Share on

Global Cervical Cancer Diagnostics and Therapeutics Market Size, Share, Trends & Growth Analysis Report - Segmented By Diagnostics Test, Methods, Therapies, End-user, and Region – Industry Forecast (2022 to 2027)

Published: March, 2023
ID: 771
Pages: 175
Formats: report pdf report excel report power bi report ppt

Cervical Cancer Diagnostics and Therapeutics Market Size (2022 to 2027)

The global Cervical Cancer Diagnostics and Therapeutics Market is estimated to be growing at a CAGR of 4.54% from 2022 to 2027. The size of the market is predicted to be USD 5272 million by 2027 from USD 4223 million in 2022.  

According to the WHO, nearly 270,000 women tend to lose their lives because of cervical cancer. Cervical cancer is the fourth most cancer among women across the world. As per WHO, an estimated 570,000 new cancer cases were registered in 2018, where 6.6% of the people were female. According to the American Cancer Society statistics, around 4,250 women in the United States lost their lives in 2019, and approximately 13,170 new cervical cancer cases were diagnosed.

Public awareness of cervical cancer care, prevention and treatment options, and certain behaviors such as sexual intercourse and smoking, certain genetic factors, and low immunity are associated with developing cervical cancer diagnostic and therapeutic market. Awareness programs can help the market grow. For example, Medicaid, a popular government insurance plan, is targeted at screening for cervical cancer.


Factors that are significantly driving the growth of the global cervical cancer diagnosis and therapeutics market include government initiatives to prevent cervical cancer, increased cancer prevalence, a rise in awareness of early diagnosis, and R&D features that support vital player strengths in cancer diagnosis and medicine. Studies have shown significant growth of cervical cancer diagnostics and treatments, attributable to the increasing prevalence of cervical cancer in women worldwide. As per the World Health Organization (WHO), over 270,000 women die each year from cervical cancer. Cervical cancer has a higher mortality rate in developing countries due to early false detection of the disease. The market is expected to grow with the increasing use of cervical cancer diagnostic tests to detect cancer early.

The emergence of reimbursement-related preferential policies is a crucial factor that is supposed to increase screening tests during the forecast period. Technology is also a critical factor in improving the accessibility and affordability of various diagnostic tests in nations like the United States. New diagnostic equipment, procedures, and technological advances in screening technology are also anticipated to impact the global cervical cancer diagnosis and therapeutics market positively. Key existing biomarkers include long non-coding RNA (lncRNA), mRNA, and m6A. The growing demand for new therapies and biomarkers to improve screening results is one of the key factors to boost market development. The Asia Pacific region is expected to be the fastest-growing cervical cancer treatment market in the forecast period. Public awareness of the disease is continuously growing, and government support and advanced diagnosis drive the development of the cervical cancer therapeutics market. Increasing investments in immunotherapy and targeted therapy R & D are creating numerous channels, further promoting this market growth.

The rising incidence of cervical cancer has led governments and non-profit organizations to take initiatives to raise awareness about the management and prevention of cervical cancer and the HPV vaccine.


The complex tests require many sampling instruments, trained pathologists and cell technicians, and continuous monitoring to get high-quality results, limiting the global cervical cancer diagnostics and therapeutics market growth. The high cost of vaccines and the lack of understanding of HPV vaccines in developing countries severely limit the global cervical cancer diagnostics and treatment market.

Impact of COVID-19 on the global cervical cancer diagnostics and therapeutics market:

The world has been placed on a high alert as a result of the novel coronavirus pandemic. The WHO announced a pandemic in the world in early March 2020. The COVID-19 has raised a major need for effective cancer screening programs for patients who cannot have direct appointments. Cervical cancer takes the lives of almost 270,000 people a year, according to the World Health Organization. Cervical cancer is the fourth most common cancer among females in the world. COVID-19 has had a huge effect on the landscape of cancer care, impacting everything from prevention to screening and diagnosis, recovery, palliative care, and patient follow-up, as well as cancer medication logistics and supplies. After this pandemic period, the market is predicted to have positive growth during the forecast period.




Market Size Available

2021 to 2027

Base Year


Forecast Period

2022 to 2027

Segments Covered

By Diagnostic Tests, Methods, Therapies, End-Users, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, APAC, Latin America, Middle East & Africa


This research report on the global cervical cancer diagnostics and therapeutics market has been segmented and sub-segmented based on the diagnostic tests, methods, therapies, end-users, and region.

Cervical Cancer Diagnostics and Therapeutics Market - By Diagnostics test:            

  • Pap Smear Test     
  • HPV Testing           
  • Colposcopy           
  • Cervical Cancer Biopsy   

Based on diagnostics tests, the Pap Smear Test segment dominated the market by Diagnostic tests, holding a 45% share in the global market for cervical cancer diagnostic tests. This segment's high growth rate can be attributed to the test's high efficiency, low cost of the test compared with other tests available in the market, and rising awareness regarding a cancer diagnosis. In 2018, the US Preventive Services Task Force updated its guidelines for screening cervical cancer as it instructs the women between 21 to 29 years should undergo Pap smear tests every 3 years.

The HPV testing segment is projected to grow at a promising CAGR of 15.3% during the forecast period. The rising need for technological advancements towards diagnostic procedures at low prices and enhancements for different biomarkers with frequent screening procedures are likely to impel the market growth. The screening test's developed accuracy and sensitivity are the important factors propelling the cancer diagnostics and therapeutics market demand.

The colposcopy segment is the quickest growing product, and the segment is projected to grow with a CAGR of 9.1% during the analysis period. Escalating cervical cancer occurrences globally and surging colonoscopies among hospitals uplift the market growth across the world.

Cervical Cancer Diagnostics and Therapeutics Market - By Methods:

  • Molecular method             
  • Cytopathological method 
  • Physical method  

Based on the method, the Cytopathological method leads the market with the highest share in the market.

Cervical Cancer Diagnostics and Therapeutics Market - By Therapies:

  • Surgery    
  • Radiation Therapy
  • Chemotherapy     
  • Other Therapies   

Based on the therapies, the chemotherapy segment is accounted to hold the highest share in the market and is projected to grow with a CAGR of 44% during the analysis period. Factors like surging the efficiency of the radiation therapy and low-dose chemotherapy are given in add-on with radiation therapy.

Other therapies segment is predicted to hike at a CAGR of 7.7% during the forecast period. The segment growth is attributed due to factors like mounting insistence among healthcare professionals.

Radiation therapy is projected to hold the second-largest share in the cervical cancer diagnostics and therapeutics market growth.

Cervical Cancer Diagnostics and Therapeutics Market - By End-users:

  • Hospitals 
  • Laboratories         
  • Independent Physicians   
  • Clinics      
  • Other End-Users 

Based on the end-user, the hospital segment is expected to lead the cervical cancer diagnostics market. The rising female population with new cervical cancer cases and regular visits to hospitals boost the market growth.

Cervical Cancer Diagnostics and Therapeutics Market - By Region:

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • The Middle East and Africa

Geographically, North America holds the largest share of the global cervical cancer diagnostics and therapeutics market, followed by Europe. Many factors such as the rising prevalence of cervical cancer, growing awareness of cervical cancer screening programs, and government support drive the growth of the HPV testing market in the North American region. Asia Pacific market is growing at a very high rate due to the rising consumer market, favorable government support for enhanced healthcare infrastructure, and raising awareness for healthcare among the population in the region's developing nations.


Some of the key market participants leading the global cervical cancer diagnostics and therapeutics market profiled in this report are Abbott Diagnostics, Alere, Beckman Coulter, Clinical Genomics, Companion Dx, EDP Biotech, Epigenomics AG, Exact Sciences, Fujirebio, Genomic Tree, Metabiomics, Oncocyte (Biotime), Quest Diagnostics, Randox Laboratories, Siemens Healthcare, and Volition Rx.


  • In the market, the new vaccines are being available at a low cost. Most cervical cancer vaccines are late in clinical development. Computer-guided cervical cancer detection technology is continually being developed to minimize false-negative tests. It is expected to drive growth in the cervical cancer diagnostic testing market, coupled with increased accuracy.
  • F. Hoffmann-La Roche Ltd. has developed a fully automated CINtec PLUS * cell test that removes unhealthy tissue from the cervix before cancer tissue grows. Roche also announced that it had received Avastin, a biopharmaceutical and chemotherapy treatment for advanced cervical cancer patients.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us:

Click for Request Sample